Citius Pharmaceuticals 주식 (NASDAQ: CTXR)

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

Citius Pharmaceuticals

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

WIIM

SLRN

ACELYRIN shares are trading higher after the company announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.

Citigroup analyst Anthony Pettinari maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Neutral and lowers the price target from $69 to $59.

Price Target

Analyst Ratings

BALL

Citigroup Maintains Neutral on Ball, Lowers Price Target to $59

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025
Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027
Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease (TED). The Company will host a virtual investor event today, Monday, January 6, 2025 at 4:30 PM ET. To register, <a href="https://www.globenewswire.com/Tracker?data=QcVAIgTRuHWL3sNaIYQ-HYj7VWmpCNLUwaU1Xu-LZfukDKKVFJ8UZSQCSu_sh_44ahsQqUh9j-n5jDFZtDm49lUjp0GvM09M6BN9cGj1kLE=">click here.</a>

Biotech

General

ACELYRIN Announces Additional Phase 2 Data And Phase 3 Program Design For Lonigutamab In Thyroid Eye Disease; Patients Demonstrate Potential For Efficacy In Line With Standard Of Care And A More Favorable Safety Profile

Ratings for Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.75, a high estimate of $75.00, and a low estimate of $56.00. A 0.4% drop is evident in the current average compared to the previous average price target of $63.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736197251_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Commercial Metals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seth Rosenfeld</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$58.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Curt Woodworth</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$56.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mike Harris</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Commercial Metals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Commercial Metals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Commercial Metals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Commercial Metals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Commercial Metals analyst ratings.</a>
<h2>About Commercial Metals</h2>
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
<h3>Key Indicators: Commercial Metals's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Commercial Metals's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately -9.64%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Commercial Metals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Commercial Metals's ROE stands out, surpassing industry averages. With an impressive ROE of 2.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.54%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Commercial Metals

In the preceding three months, 11 analysts have released ratings for Republic Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $226.82, a high estimate of $244.00, and a low estimate of $217.00. This upward trend is apparent, with the current average reflecting a 5.77% increase from the previous average price target of $214.45.
<img src="https://www.benzinga.com/files/images/story/2025/1736197243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Republic Servs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$237.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Faiza Alwy</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$237.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$238.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$227.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$217.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Arthur Nagorny</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$219.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$244.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Republic Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Republic Servs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Republic Servs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Republic Servs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RSG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Republic Servs analyst ratings.</a>
<h2>About Republic Servs</h2>
Republic Services is the second-largest integrated provider of traditional solid waste services in the United States, operating roughly 207 active landfills and 246 transfer stations. The company serves residential, commercial, and industrial end markets. It also runs a sizable recycling operation in North America.
<h3>Breaking Down Republic Servs's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Republic Servs showcased positive performance, achieving a revenue growth rate of 6.54% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Republic Servs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Republic Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.09% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Republic Servs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Republic Servs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.14.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Have This To Say About Republic Servs

CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $36.5, a high estimate of $40.00, and a low estimate of $33.00. Surpassing the previous average price target of $34.75, the current average has increased by 5.04%.
<img src="https://www.benzinga.com/files/images/story/2025/1736197235_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of CECO Environmental among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Spychalla</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Bobby Brooks</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CECO Environmental. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CECO Environmental compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CECO Environmental's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CECO Environmental's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CECO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CECO Environmental analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About CECO Environmental</h2>
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
<h3>CECO Environmental: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: CECO Environmental's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -9.29%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: CECO Environmental's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CECO Environmental's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.34%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.66, CECO Environmental adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CECO

What 4 Analyst Ratings Have To Say About CECO Environmental

Analysts' ratings for Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $51.11, with a high estimate of $58.00 and a low estimate of $41.00. This current average reflects an increase of 10.58% from the previous average price target of $46.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1736197228_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Build-A-Bear Workshop among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Build-A-Bear Workshop. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Build-A-Bear Workshop compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Build-A-Bear Workshop's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Build-A-Bear Workshop's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Build-A-Bear Workshop analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Build-A-Bear Workshop's Background</h2>
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
<h3>Build-A-Bear Workshop: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Build-A-Bear Workshop displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 11.03%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Build-A-Bear Workshop's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.26% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.76%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Build-A-Bear Workshop's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.49%, the company showcases efficient use of assets and strong financial health.
Debt Management: Build-A-Bear Workshop's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.76.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Build-A-Bear Workshop In The Eyes Of 9 Experts

Analysts' ratings for Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) over the last quarter vary from bullish to bearish, as provided by 18 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $66.44, a high estimate of $75.00, and a low estimate of $56.00. This upward trend is apparent, with the current average reflecting a 6.05% increase from the previous average price target of $62.65.
<img src="https://www.benzinga.com/files/images/story/2025/1736197217_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Kroger is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Rob Dickerson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kroger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Kroger compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Kroger's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Kroger's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kroger analyst ratings.</a>
<h2>About Kroger</h2>
Kroger is one of the largest grocery retailers in the United States with more than 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The firm also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
<h3>A Deep Dive into Kroger's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining Kroger's financials over 3 months reveals challenges. As of 31 October, 2024, the company experienced a decline of approximately -0.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Kroger's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kroger's ROE stands out, surpassing industry averages. With an impressive ROE of 4.86%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Kroger's ROA stands out, surpassing industry averages. With an impressive ROA of 1.09%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Kroger's debt-to-equity ratio surpasses industry norms, standing at 2.31. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Kroger Stock: Analyst Perspectives (18 Ratings)

13 analysts have expressed a variety of opinions on AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AZEK Co, revealing an average target of $55.62, a high estimate of $64.00, and a low estimate of $49.00. Surpassing the previous average price target of $50.46, the current average has increased by 10.23%.
<img src="https://www.benzinga.com/files/images/story/2025/1736197210_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AZEK Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Susan Maklari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Kurt Yinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AZEK Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AZEK Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AZEK Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into AZEK Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AZEK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AZEK Co analyst ratings.</a>
<h2>All You Need to Know About AZEK Co</h2>
The AZEK Co Inc is a designer and manufacturer of beautiful, low maintenance and environmentally sustainable products focused on the fast-growing Outdoor Living market. Its portfolio of products includes decks, rail, trim, outdoor furniture among others. The company operates in two segments: Residential Segment that manufactures and distributes decking, railing, trim, moulding, pergolas and cabanas and accessories through a national network of dealers and distributors and multiple home improvement retailers; and Commercial Segment that manufactures, fabricates and distributes lockers and bathroom partitions. It generates maximum revenue from the Residential segment. The company's brand includes TimberTech; AZEK; Versatex, Ultralox, StruXure, and Intex.
<h3>AZEK Co: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AZEK Co's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -10.44%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: AZEK Co's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 8.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.06%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.26%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: AZEK Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZEK

Expert Outlook: AZEK Co Through The Eyes Of 13 Analysts

Citigroup analyst Anthony Pettinari maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Neutral and lowers the price target from $228 to $202.

Citigroup Maintains Neutral on Avery Dennison, Lowers Price Target to $202

Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) unveiled Monday an extensive lineup of next-generation processors and gaming products ahead of Consumer Electronics Show 2025 in Las Vegas, targeting the growing demand for high-performance AI-enabled PCs, gaming <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42822846/nvidia-5000-series-product-updates-make-it-top-semiconductor-pick-ahead-of-jensen-huangs-ces-keynote-analyst">systems, and mobile devices.</a>
<h3 class="wp-block-heading">Next-Gen Processors: AI PCs And Enterprise Innovation</h3>
AMD introduced the Ryzen AI Max Series, Ryzen AI 300 Series, and Ryzen AI 200 Series processors, built on AMD's Zen 5 and Zen 4 architectures. These processors cater to a variety of users, from premium thin-and-light notebooks to everyday productivity tasks. 
For enterprise users, AMD expanded its Ryzen PRO Series lineup, integrating advanced AMD PRO Technologies for security and IT manageability.
"With the next generation of AI-enabled processors, we are proliferating AI to devices everywhere, bringing the power of a workstation to thin and light laptops," said Jack Huynh, AMD's senior vice president and general manager of Computing and Graphics.
The flagship Ryzen AI Max processors boast up to 16 Zen 5 CPU cores, 40 AMD RDNA 3.5 graphics compute units, and an AMD XDNA 2 Neural Processing Unit capable of 50 trillion operations per second. Systems powered by these processors will be available starting in the first quarter 2025.
<h3 class="wp-block-heading">Gaming: Pushing Desktop And Mobile Performance Limits</h3>
AMD's gaming announcements were headlined by the new Ryzen 9950X3D and Ryzen 9900X3D desktop processors, featuring 2nd-generation 3D V-Cache technology for unprecedented gaming and content-creation performance. Both processors are based on AMD's Zen 5 cores and optimized for high clock speeds and lower temperatures.
For handheld gaming enthusiasts, AMD launched the Ryzen Z2 Series processors, promising AAA gaming experiences on portable devices with up to 8 cores and AMD RDNA 3.5 architecture. These systems are also slated for release in the first quarter of the year.
&#8220;Gaming has become one of the biggest forms of entertainment worldwide,&#8221; Huynh stated, adding, &#8220;Today's announcements underscore our commitment to delivering hardware that eliminates performance bottlenecks for gamers."
Read Also: <a href="https://www.benzinga.com/25/01/42818093/amd-and-stradvision-team-up-to-boost-adas-backed-by-trump-and-musks-vision-for-autonomous-cars">AMD, StradVision Team Up To Boost Driver Assistance Systems For Autonomous Cars</a>
<h3 class="wp-block-heading">Collaboration With Dell</h3>
AMD also announced its Ryzen AI PRO processors will power Dell Technologies Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) new commercial PC lineup.
These devices mark Dell's first use of AMD's AI-focused silicon in enterprise PCs, a milestone in their long-standing partnership.
"We're incredibly proud to collaborate with Dell on the next generation of commercial PCs," Huynh said. 
Sam Burd, President of the Client Solutions Group at Dell Technologies, highlighted the importance of AI innovation, stating, "AI PCs represent the next frontier in computing, transforming how we work, create and connect."
<h3 class="wp-block-heading">Market Reactions</h3>
Minutes after the product announcements, AMD shares briefly dipped before rebounding, supported by optimistic projections for its AI and gaming processors. 
At the time of writing, AMD stock was up 3.8% intraday, though still down over 7% year-over-year.
Shares of Dell Technologies were also 3.8% higher by 3:40 p.m. ET, holding session gains. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/01/42827345/nvidia-soars-amd-stalls-ai-race-heats-up-at-ces-2025">Nvidia Soars, AMD Stalls: AI Race Heats Up At CES 2025</a></li>
</ul>
Photo: Shutterstock

Large Cap

Events

Tech

DELL

AMD Unveils 'Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025

Citigroup analyst Anthony Pettinari maintains Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) with a Buy and lowers the price target from $4.5 to $4.

AMBP

Citigroup Maintains Buy on Ardagh Metal Packaging, Lowers Price Target to $4

Citigroup analyst Anthony Pettinari maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Buy and lowers the price target from $325 to $301.

Citigroup Maintains Buy on Vulcan Materials, Lowers Price Target to $301

Citigroup analyst Anthony Pettinari maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $84 to $78.

TREX

Citigroup Maintains Neutral on Trex Co, Lowers Price Target to $78

<ul>
<li>HERE enters into 10-year, $1 billion cloud infrastructure agreement with AWS to support AI-powered, live streaming map and location services for automotive, transportation, logistics, and mobility companies globally.</li>
<li>HERE and AWS combine expertise for new offers to enhance and accelerate automakers' development of electric, automated, and software-defined vehicles. &nbsp;</li>
</ul>
Las Vegas, CES 2025 – <a href="https://www.globenewswire.com/Tracker?data=pCDXH0oD7U9TBn9JWf3VIiMsfjbO9xvu-cD-Fvl2eGNlv4dw0-RKWGjRS9D4p95MtfpC-PEA0bVEczcb9jyTog==">HERE Technologies</a> (HERE) and <a href="https://www.globenewswire.com/Tracker?data=4TC2cpbzU6UhbefFLk_UYh2l36djPeFWhxP0wlx-WbnoFJKYTBEyNlmWuKGFpYQsPptCJ7zlzjZvX6BfaydZlU52E6puVz7OAc8cruYDSQ4=">Amazon Web Services, Inc.</a> (AWS), an Amazon.com company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), today announced their new collaboration and cloud infrastructure agreement, to provide a scalable and streamlined solution for automakers' development of location-aware software. This collaboration will advance Software-Defined Vehicle (SDV) development and combining AWS technologies with HERE mapping solutions will help accelerate the development of Advanced Driver Assistance Systems (ADAS), Automated Driving (AD), and new digital car experiences.

Contracts

AMZN

Reported Earlier, HERE Enters Into 10-Year, $1B Cloud Infrastructure Agreement With AWS To Support AI-Powered, Live Streaming Map And Location Services For Automotive, Transportation, Logistics, And Mobility Companies Globally

Calamos Investments skipped into 2025 with the launch of two Structured Protection ETFs, the Calamos S&amp;P 500 Structured Alt Protection ETF — January (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPSY#NYSE">CPSY</a>) and the Calamos Russell 2000 Structured Alt Protection ETF- January (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRY#NYSE">CPRY</a>). 
These funds, launched on Jan. 2, offer equity market exposure with a protective moat, keeping in mind risk-averse investors seeking equity exposure with downside protection.
See Also: <a href="https://www.benzinga.com/25/01/42829188/hack-attack-cybercrime-surge-fuels-demand-for-cybersecurity-etfs">Cybercrime Surge Fuels Demand For Cybersecurity ETFs</a>
Specifically, Calamos S&amp;P 500 Structured Alt Protection ETF — January provides exposure to the S&amp;P 500 with a starting cap rate of 7.57% gross of fees annual expense ratio, according to the fact sheet released by Calamos. 
Meanwhile, the Russell 2000 Structured Alt Protection ETF — January mirrors the Russell 2000, offering a higher starting cap rate of 9.59% gross of fees. Both ETFs deliver 100% downside protection (no capital-loss) over a one-Both ETFs deliver 100% downside protection (no capital-loss) over a one-year outcome period, excluding fees and expenses.year outcome period, excluding fees and expenses.
<h3 class="wp-block-heading">What Sets These Funds Apart</h3>
Investors can book gains up to a pre-set cap, depending on the performance of their respective indexes. 
Tax advantages are another reason investors with lower risk appetite lean towards these ETFs. More specifically, gains can be taxed at long-term capital rates, creating the potential of a tax alpha, while monthly entry points allow investors the flexibility to plan their allocation. The expense ratio is 0.69%, although on the higher end, seems reasonable given the options strategy and downside protection that come with the fund.
<h3 class="wp-block-heading">Why It Matters In 2025</h3>
Calamos continues to expand its Structured Protection ETF docket, taking diverse investor needs into consideration. Previous fund performances, such as that of the Calamos Laddered S&amp;P 500 Structured Alt Protection ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPSL#NYSE">CPSL</a>), have been successful, and had attracted more than $40 million in flows since September 2024. This shows that Calamos ETFs are gaining popularity among investors. Amid uncertainty from inflation and volatility, as well as other resource-draining global issues like wars, these ETFs carefully approach investing with a balance between risk and reward. 
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42823961/indexperts-kicks-off-2025-with-3-etfs-offering-growth-stability-income-during-market-volatility">Indexperts Kicks Off 2025 With 3 ETFs Offering Growth, Stability, Income During Market Volatility</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

New ETFs

ETFs

CPRY

CPSL

Calamos ETF Trust Calamos S&P 500 Structured Alt Protection ETF January

CPSY

Calamos Boosts Structured Protection Offerings With Two New ETFs For 2025

PYCR

Paycor HCM shares are trading higher. JMP Securities reiterated a Market Outperform rating on the stock while Needham reiterated a Buy rating.

Citigroup analyst Anthony Pettinari maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Neutral and lowers the price target from $155 to $137.

Citigroup Maintains Neutral on Toll Brothers, Lowers Price Target to $137

NMRA

Neumora Therapeutics shares are trading higher. B of A Securities maintained a Buy rating on the stock.

KULR Technology Group, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) shares are trading higher Monday after the company announced it purchased millions of <a href="https://www.benzinga.com//node/42812844">dollars worth of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</a>.
The Details: In a new regulatory filing, KULR Technology unveiled the purchase of 213.43 bitcoin for approximately $21 million, resulting in a weighted average cost of $98,393.58 per bitcoin.
The company's $21 million purchase has doubled its total bitcoin purchases to date to $42 million. The latest purchase is in line with KULR Technology&#8217;s commitment to hold up to 90% of its surplus cash reserves in bitcoin.
When KULR announced its bitcoin treasury strategy in early December, the company had around $12 million in cash. The company said Monday its bitcoin acquisitions will be guided by market dynamics and anticipated cash flow needs, with the flexibility to adjust the strategy as circumstances evolve.
KULR Technology noted that its bitcoin yield was 93.7% from the company's initial bitcoin purchase in December through Jan. 4.
&#8220;We believe the growing global acceptance of bitcoin is still in its early stages. Companies, financial institutions, governments, and the capital markets are recognizing and incorporating blockchain technology, and specifically, BTC into their overall economic toolkits,&#8221; said KULR Chairman and CEO Michael Mo.
&#8220;Given the unique characteristics of BTC, it provides long term appreciation and a bulwark against geopolitical, inflationary, and other macro-economic and political trends affecting all developed economies. Given our improved balance sheet, including increased cash balances, I am confident that a bitcoin treasury strategy will strengthen KULR&#8217;s financial position as we work to expand operations and manage our financial capital responsibly by adding an independent treasury reserve.&#8221;
It&#8217;s worth noting that Bitcoin prices were moving higher at the time of writing Monday. Bitcoin was up about 3.65% over a 24-hour period, hovering around $102,000 at last check.
Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/25/01/42826581/what-12-analyst-ratings-have-to-say-about-hims-hers-health">What 12 Analyst Ratings Have To Say About Hims &amp; Hers Health</a>
KULR Price Action: At the time of publication, KULR shares were up 3.01% at $3.42, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image via Shutterstock

Movers

$BTC

KULR

What's Going On With KULR Technology Stock Monday?

D. Boral Capital downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy without a price target following the company's announcement of a 1-for-2...

Citius Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital

Citius Pharmaceuticals (CTXR) announced that the company held a constructive in-person Type C meeting with the U.S. FDA. The meeting followed succe...

Citius Pharmaceuticals reports 'constructive' FDA Type C meeting on Mino-Lok

19:50 EST Citius Pharmaceuticals (CTXR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...

Citius Pharmaceuticals trading halted, news pending

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CTXR stock, giving a Buy rating on November 12. Michael Okunewitch ha...

Promising Outlook for Citius Pharmaceuticals: Buy Rating Affirmed Amid Product Potential and Strategic Developments

Citius Pharma ( ($CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pha...

Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharmaceuticals GAAP EPS of -$5.97

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusi...

Citius Oncology to explore strategic alternatives

AMTM

ARQT

ARTV

AXSM

CTOR

HSAI

MSTR

NAMS

NUVL

NVDA

RCKT

RHHBY

RHHVF

SEAT

TLRY

TTWO

VCSA

WKSP

Screenshot 2024-08-06 at 7.17.40 PM

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Earnings

Press Releases

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Stock Split

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

AN2 Therapeutics

Athira Pharma

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cocrystal Pharma

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

IGC Pharma

Opus Genetics

Iterum Therapeutics

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

SCYNEXIS

Traws Pharma

VYNE Therapeutics

D. Boral Capital

HC Wainwright & Co.

EF Hutton

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다.
1. 셀 사이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) 
벤징가 프로 데이터에 따르면 셀 사이는 5백만 달러 규모 공모에 대해 1,614만 보통주 가격을 주당 31센트로 책정했다. 주가는 시간외 거래에서 8.6% 하락한 0.55달러를 기록했다.
2. CCSC 테크놀로지 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) 
CCSC 테크놀로지는 9월 30일 종료된 6개월 동안 70만 달러의 순손실을 기록했고, 전년 동기 순이익은 40만 달러였다. 같은 기간 매출은 전년 동기 대비 22.9% 증가한 920만 달러를 기록했다. 주가는 시간외 거래에서 49.4% 상승한 2.45달러였다.
3. 루나 이노베이션스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) 
루나 이노베이션스는 이사회 멤버인 파멜라 코(Pamela Coe)가 은퇴할 것이라고 발표했다. 주가는 시간외 거래 세션에서 5.5% 하락한 2.05달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 시티우스 파마슈티컬스 (NASDAQ:<a href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR)</a> 
시티우스 파마슈티컬스는 9월 30일로 마감된 회계연도에 3,940만 달러(주당 5.97달러)의 순손실을 기록했으며, 전년 동기 순손실은 3,250만 달러(주당 5.57달러)였다. 주가는 시간외 거래 세션에서 1.9% 하락한 1.0207달러를 기록했다.
5. 지니어스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>)
지니어스 그룹의 상반기 매출은 전년 동기 1,180만 달러에서 490만 달러로 감소했다. 순자산은 2023년 12월 31일 기준 1,970만 달러에서 5,460만 달러로 177% 급증했다. 주가는 시간외 거래 세션에서 11.6% 상승한 0.72달러로 마감했다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Citius Pharmaceuticals

뉴스

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

월요일, 12월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌